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ABSTRACT
Objective To investigate whether angiotensin receptor
blockers protect against Alzheimer’s disease and
dementia or reduce the progression of both diseases.
Design Prospective cohort analysis.
SettingAdministrative database of the USVeteran Affairs,
2002-6.
Population 819491 predominantly male participants
(98%) aged 65 or more with cardiovascular disease.
Main outcome measures Time to incident Alzheimer’s
disease or dementia in three cohorts (angiotensin
receptor blockers, lisinopril, and other cardiovascular
drugs, the “cardiovascular comparator”) over a four year
period (fiscal years 2003-6) using Cox proportional
hazard models with adjustments for age, diabetes,
stroke, and cardiovascular disease. Disease progression
was the time to admission to a nursing home or death
among participants with pre-existing Alzheimer’s disease
or dementia.
Results Hazard rates for incident dementia in the
angiotensin receptor blocker group were 0.76 (95%
confidence interval 0.69 to 0.84) compared with the
cardiovascular comparator and 0.81 (0.73 to 0.90)
compared with the lisinopril group. Compared with the
cardiovascular comparator, angiotensin receptor
blockers in patients with pre-existing Alzheimer’s disease
were associated with a significantly lower risk of
admission to a nursing home (0.51, 0.36 to 0.72) and
death (0.83, 0.71 to 0.97). Angiotensin receptor blockers
exhibited a dose-response as well as additive effects in
combination with angiotensin converting enzyme
inhibitors. This combination compared with angiotensin
converting enzyme inhibitors alone was associated with a
reduced risk of incident dementia (0.54, 0.51 to 0.57) and
admission to a nursing home (0.33, 0.22 to 0.49). Minor
differences were shown in mean systolic and diastolic
blood pressures between the groups. Similar results were
observed for Alzheimer’s disease.
Conclusions Angiotensin receptor blockers are
associated with a significant reduction in the incidence
and progression of Alzheimer’s disease and dementia
compared with angiotensin converting enzyme inhibitors
or other cardiovascular drugs in a predominantly male
population.
INTRODUCTION
Dementia, including Alzheimer’s disease, is one of the
major threats to public health as people age. Dementia
is also an important economic cost to society because
affected people may spend extended periods in nur-
sing homes. The causes of dementia, and Alzheimer’s
disease in particular, are complex, but evidence
increasingly points to three main risk factors—age,
the accumulation of amyloid β in the brain, and the
deterioration of the cardiovascular system. Cardio-
vascular dysfunction is also strongly related to other
forms of dementia. Studies have found that cardio-
vascular risk factors inmid-life, such as hypercholester-
olaemia, hypertension, and diabetes contribute to
the development of dementia.1-5 Drugs used to treat
these risk factors may also reduce the incidence of
dementia.6-11
Pharmacotherapy targeting the renin-angiotensin
system is one of the most effective means of reducing
hypertension and cardiovascular morbidity.12 13 Renin
is a protease that cleaves angiotensinogen to produce
angiotensin I, which is then cleaved by angiotensin
converting enzyme to produce the bioactive peptide
angiotensin II.14 Angiotensin II binds to multiple
receptors, with the AT1 and AT2 receptors being the
best studied and most abundant angiotensin II recep-
tors in the vasculature. Both receptors are present in
brain and vasculature.15 They seem to function in
opposition.16 The mechanism of action of AT2 recep-
tors remains to be fully elucidated, but in the rat the
receptors inhibit endothelial cell proliferation and pro-
mote axonal regeneration.17 18
Multiple studies have shown that angiotensin con-
verting enzyme inhibitors prevent the action of angio-
tensin II and are the most effective agents for lowering
blood pressure.12 13 Their efficacy has led to this class of
drugs being designated as a primary treatment for
hypertension. These drugs are also associated with
lower rates of congestive heart failure, myocardial
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ischaemia, renal disease, and death than hypertensive
drugs acting through othermechanisms.12 13 Two small
studies found that angiotensin converting enzyme inhi-
bitors reduced rates of cognitive decline.19 20
Drugs that selectively inhibit the AT1 receptor are
termed angiotensin receptor blockers. These drugs
reduce blood pressure and protect against cardio-
vascular outcomes such as myocardial infarction and
atrial fibrillation although with slightly less efficacy
than angiotensin converting enzyme inhibitors.12 13
Angiotensin receptor blockers also protect against dia-
betes, possibly with greater efficacy than angiotensin
converting enzyme inhibitors.21-23 The Valsartan
Heart Failure Trial (Val-HeFT) suggested that angio-
tensin receptor blockers and angiotensin converting
enzyme inhibitors exhibit added benefit for cardio-
vascular outcomes when used in combination, but
this was not observed in theCandesartan inHeart Fail-
ure: Assessment of Reduction in Mortality and Mor-
bidity (CHARM) study.24 25 An increasing number of
studies have shown a relation between angiotensin
receptor blockers and preservation of cognitive
function.26 Studies in both animals and humans found
that angiotensin receptor blockers help to preserve
cognitive function through a mechanism that is inde-
pendent of the antihypertensive effects.27-31 Compre-
hensive summaries on the role of the renin-
angiotensin system in Alzheimer’s disease and the
effects on cognitive function of drugs that inhibit the
renin-angiotensin system have been reviewed.32 33 On
the basis of these data the effect of angiotensin receptor
blockers and angiotensin converting enzyme inhibi-
tors on dementia outcomes should be evaluated.
We investigated whether angiotensin receptor
blockers protect against dementia andAlzheimer’s dis-
ease and reduce the progression of these diseases in a
large population with uniform healthcare coverage.
METHODS
This study used information from the Veterans health
system decision support system database, which con-
tains records on about 4.5 million people annually in
the US Veterans Affairs health system from fiscal year
2002 (1 October 2001) to end of fiscal year 2006 (30
September 2006); over the five years of the study the
records totalled about 7.3 million people.34 For studies
of incident Alzheimer’s disease and dementia we used
records from the first year of the database, fiscal year
2002, as a baseline to ensure that participants were free
of these diseases for at least one year, and we restricted
the analytical part of the study to fiscal years 2003-6.
The sample sizes were more than 11 500 for the angio-
tensin receptor blockers group, more than 91 000 for
the lisinopril group, and more than 696 000 for the
cardiovascularcomparatorgroup;seewebextra table 1
on bmj.com.
We included adults aged 65 or more as of 1 October
2002. Disease codes are those used in ICD-9 (inter-
national classification of diseases, ninth revision). The
analysis of incidence was restricted to those without a
previous diagnosis of Alzheimer’s disease (code 331.0)
or dementia (291, 294, 331.0) as judged by an absence
of the diagnosis from fiscal year 2002 or up to the point
of initiation of the targeted drugs for participants who
started taking the drugs after fiscal year 2002. We
restricted the analysis of disease progression to those
Table 1 | Personal details of participants analysed in study. Values are numbers (percentages) unless stated otherwise
Variables
Alzheimer’s disease (n=819 491) Dementia (n=799 069)
Angiotensin receptor
blocker (n=11 703)
Lisinopril
(n=93 484)
Cardiovascular comparator
(n=714 304)
Angiotensin receptor
blocker (n=11 507)
Lisinopril
(n=91 164)
Cardiovascular comparator
(n=696 398)
Mean (SD) age (years) 74 (5.5) 74 (5.6) 75 (5.9) 74 (5.5) 74 (5.5) 75 (5.9)
Race:
Hispanic, white 101 (0.9) 2872 (3.1) 14 088 (2.0) 96 (0.8) 2729 (3.0) 13 395 (1.9)
Hispanic, black 6 (0.05) 209 (0.22) 1168 (0.16) 6 (0.05) 200 (0.22) 1132 (0.16)
Native American Indian 8 (0.07) 88 (0.09) 653 (0.09) 8 (0.07) 85 (0.09) 638 (0.09)
Black 232 (2.0) 2398 (2.6) 31 374 (4.4) 222 (1.9) 2240 (2.5) 29 816 (4.3)
Asian 35 (0.3) 210 (0.2) 1285 (0.2) 35 (0.3) 200 (0.2) 1222 (0.2)
White 3157 (27) 28 976 (31) 256 442 (36) 3087 (27) 28 082 (31) 248 607 (36)
Unknown 8164 (70) 58 731 (63) 409 294 (57) 8053 (70) 57 628 (63) 401 588 (58)
Men 11 392 (97) 91 881 (98) 701 201 (98) 11 205 (97) 89 641 (98) 683 690 (98)
Women 311 (3) 1603 (2) 13 103 (2) 302 (3) 1523 (2) 12 708 (2)
Diseases:
Hypertension 10 857 (93) 85 441 (91) 571 673 (80) 10 676 (93) 83 324 (91) 557 617 (80)
Cardiovascular disease 3967 (34) 28 087 (30) 357 331 (50) 3886 (34) 27 218 (30) 347 973 (50)
Diabetes 4090 (35) 38 731 (41) 151 945 (21) 4020 (35) 37 784 (41) 147 687 (21)
Stroke 1449 (12) 12 776 (14) 114 183 (16) 1390 (12) 11 933 (13) 107 554 (15)
Blood pressure*: n=1078 n=5439 n=45 978 n=988 n=5012 n=42 843
Mean (SD) systolic blood pressure 136 (13) 134 (13) 133 (14) 136 (13) 134 (13) 133 (14)
Mean (SD) diastolic blood pressure 74 (8) 73 (8) 71 (8) 74 (8) 73 (8) 72 (8)
*Subsample of patients from Veteran Affairs Vertically Integrated Service Network 1.
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with an existing diagnosis of Alzheimer’s disease or
dementia; only events after the diagnosis of dementia
were used for the study of progression. To establish
exclusion criteria we used a floating starting point.
The time to event was measured from the first record
of the drug to the occurrence of the event (diagnosis of
dementia orAlzheimer’s disease, nursing homeadmis-
sion, or death). For participants lacking events before
the end of fiscal year 2006 we defined the time to event
as censored.
Comparators and models
We examined three cohorts: those taking angiotensin
receptor blockers, those taking the angiotensin con-
verting enzyme inhibitor lisinopril, and those taking
cardiovascular drugs (drugs with a “CV” designation
in the Veterans Affairs formulary, excluding angio-
tensin receptor blockers, statins, and angiotensin
converting enzyme inhibitors), the “cardiovascular
comparator.” The lisinopril group represents a com-
parator group of a similar drug class to that of angio-
tensin receptor blockers because of shared indications
for use. We specifically selected lisinopril because it is
has the largest groupof users and longest history of use.
To control for potential biases related to selection of
one particular angiotensin converting enzyme inhibi-
torwe also examined a comparator group of the cohort
using other angiotensin converting enzyme inhibitors
(see fig 3, table 5, and web extra table 5). We also
examined a second group comprising people taking
cardiovascular drugs other than angiotensin receptor
blockers, the cardiovascular comparator group. We
examined this group because overlap between the
site of action of angiotensin converting enzyme inhibi-
tors and angiotensin receptor blockers could mute a
potentially beneficial effect of angiotensin receptor
blockers. The cardiovascular comparator group con-
tained people with similar morbidity profiles to that
of the angiotensin receptor blocker group but com-
prised a much broader group of drugs than the angio-
tensin converting enzyme inhibitor group. We
determined drug use on the basis of two criteria: a
drug possession ratio of 80% or greater for the respec-
tive drug during the six months after entry into the
study, and no exposure to the other study drugs on
entry and during the first six months of the study. We
carried out secondary analyses on outcomes in people
who switched from angiotensin converting enzyme
inhibitors to angiotensin receptor blockers, or vice
versa, and the dose-response profiles for angiotensin
receptor blocker use.
The studydesignusedmultiple strategies to dealwith
potential sources of bias. To avoid bias due to misclas-
sification we chose cohorts who shared similar health
profiles. Lisinopril and angiotensin receptor blockers
are both antihypertensives that modulate angiotensin
signalling. Drugs used by the cardiovascular compara-
tor included β blockers and calcium channel antago-
nists. To investigate bias arising from differences in
comorbidities andhealthprofileswe compared risk fac-
tors for each cohort; these were similar between the
groups (table 1). Because data on blood pressure
were not available from the national Veteran Affairs
decision support system database at the time of this
study, we determined mean blood pressures for each
cohort on the basis of a subsample from the Veterans
Affairs health system vertically integrated service net-
work.We randomly sampled eight values each for sys-
tolic anddiastolic bloodpressure for all the people from
each cohort in the Vertically Integrated Service Net-
works 1, 2, and 3, as a subset analysis and then deter-
mined mean systolic and diastolic values for each
patient. To avoid bias from reliance on prescription
data we required participants to have a drug possession
ratio of 80% or greater. High possession ratios imply
that patients are using up their drugs in the expected
period of time, corresponding with consistent use of
the drug. We examined losses to follow-up for each
cohort. These did not differ (see web extra table 2).
Drug use after entry to the study was not restricted,
except for the studies of additive effects and switching
in which we controlled for exposure to drugs in the
other two cohorts after entry into the study. Allowing
for multiple exposure maintained adequate sample
sizes for subgroup analyses and adequate statistical
power. We also examined the data on disease progres-
sion using a model that excludes polypharmacy after
entry to the study; using this approach we obtained
similar effects for trend, but the changes did not achieve
statistical significance given the inadequate power.
We examinedmultiple models. Firstly, we used age,
stroke (code 430-434), hypertension (401-405, and
459.3), cardiovascular disease (429.2, 410-414, 428,
430-438, and 440), and diabetes (250) as covariates.
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Fig 1 | Survival function for incident Alzheimer’s disease and
incident dementia in study cohorts
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We removed hypertension when we observed no sig-
nificant covariation in themultivariatemodel. Because
angiotensin receptor blockers are often prescribed to
people with renal insufficiency, we examined a sepa-
rate model incorporating renal disease as a covariate;
people with renal insufficiency were defined as those
with glomerular filtration rates of less than 60 ml/min
using a formula defined by the Renal Disease Study
Group.35
Outcomes
For the analysis of disease progression we studied the
time to admission to a nursing homeor death. Previous
clinical studies have successfully used new medical
diagnoses or events as proxies for progression of Alz-
heimer’s disease. Time to being admitted to institu-
tional care, for example, has been used as a criterion
for evaluation of the clinical efficacy of putative thera-
peutics forAlzheimer’s disease inmultiple prospective
clinical trials.36-39 Death is also a robust criterion for
progression of Alzheimer’s disease.36 38 40 The demon-
stration of utility for time to admission to institutional
care provides good support for the use of these mea-
sures as proxies for the progression of Alzheimer’s dis-
ease in the current study. Outcomes of progressive
disease were based on the well documented and vali-
dated Beneficiary and Identification Records Locator
Subsystem files for occurrence of deaths that included
date of recorded death, and Veteran Affairs nursing
home files for date of being admitted to institutional
care. All files were merged on unique identifiers
using scrambled social security numbers and then
stripped of these identifiers for confidentiality.
Strategy for analysis
We used Cox proportional hazard models to obtain
hazard rates between the angiotensin receptor blocker
group and comparators, which considers the time to
events. Censoring was defined by three criteria: end
of study (30 September 2006); losses to follow-up
determined from three database files on clinic visits,
diagnoses, and procedures; and death.
Statistical analyses
For all statistical calculations we used SAS version 9.01
software. Covariates for the Cox proportional hazard
models were age, stroke, hypertension, cardiovascular
disease, and diabetes. We carried out data manage-
ment formissing values on covariates and the outcome
variable (time to event). During the main study period
(fiscal years 2003-6), we identified 6 867 768 patients
from the diagnosis database. Only 6630 (<0.1%) were
missing date of birth. By selecting people aged 65 or
older on 1 October 2002, those missing date of birth
were automatically excluded. Covariates were coded
as present (1) or absent (0) based on diagnoses during
the study period. If disease codes for a particular con-
dition were missing, we regarded the condition as
absent (0). Outcomes were defined as time to events,
and missing events would appear as time censored
either as a result of end of study or losses to follow-up
or death (with the exception of the study of progres-
sion, where death is defined as an event).
Point estimates and 95% confidence intervals from
Cox proportional hazards models are reported for the
adjusted hazard rates. Outcomes for each cohort were
plotted with a log(−log(time)) v log(time) graph. The
curves were parallel, validating the application of the
Cox proportional hazards model. We also tested the
Weibull model for a sensitivity analysis and obtained
similar results.
RESULTS
After exclusions, 819 491 participants were available
for the study of incident Alzheimer’s disease and
799 069 for the study of incident dementia (table 1).
The number of participants with existing Alzheimer’s
disease for the study of disease progression (admission
to a nursing home) was 12 574 (476 in the angiotensin
receptor blocker group, 3227 in the lisinopril group,
and 8871 in the cardiovascular comparator group,
see web extra table 2) and with dementia was 44 601
(1920 in the angiotensin receptor blocker group,
12 064 in the lisinopril group, and 30 617 in the cardio-
vascular comparator group). Overall, 12 879 partici-
pants with Alzheimer’s disease (491 in the
Table 2 | Cox proportional hazard model for association between angiotensin receptor blockers and incidence of Alzheimer’s
disease or dementia
Variables
Incidence of Alzheimer’s disease Incidence of dementia
Estimate (SE) P value Hazard rate (95% CI) Estimate (SE) P value Hazard rate* (95% CI)
Angiotensin receptor blocker
v lisinopril
−0.213 (0.089) 0.016 0.81 (0.68 to 0.96) −0.207 (0.053) <0.001 0.81 (0.73 to 0.90)
Angiotensin receptor blocker
v cardiovascular comparator
−0.171 (0.085) 0.045 0.84 (0.71 to 1.00) −0.269 (0.051) <0.001 0.76 (0.69 to 0.84)
Lisinopril v cardiovascular
comparator
0.043 (0.029) 0.145 1.04 (0.99 to 1.11) −0.061 (0.017) 0.0004 0.94 (0.91 to 0.97)
Age 0.101 (0.001) <0.001 1.11 (1.10 to 1.11) 0.087 (0.001) <0.001 1.09 (1.09 to 1.09)
Cardiovascular disease −0.011 (0.017) 0.505 0.99 (0.96 to 1.02) 0.062 (0.010) <0.001 1.06 (1.04 to 1.09)
Diabetes 0.039 (0.020) 0.049 1.04 (1.00 to 1.08) 0.158 (0.011) <0.001 1.17 (1.15 to 1.20)
Stroke 0.694 (0.018) <0.001 2.00 (1.93 to 2.07) 0.940 (0.010) <0.001 2.56 (2.51 to 2.61)
*Adjusted for age, stroke, cardiovascular disease, and diabetes.
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angiotensin receptor blocker group, 3333 in the lisino-
pril group, and 9055 in the cardiovascular comparator
group) and 45 724 with dementia (1980 in angiotensin
receptor blocker group, 12 483 in lisinopril group, and
31 261 in the cardiovascular comparator group) were
included in the study ofmortality. Themean follow-up
times are described in web extra table 3. The charac-
teristics of the groups used for analysis of Alzheimer’s
disease and for dementia were similar (table 1). The
mean age of each group was 74 years, and the partici-
pants were largely men (98%).
The prevalence of general cardiovascular disease
and stroke was lower for the angiotensin receptor
blocker and lisinopril groups than for the cardio-
vascular comparator, but the prevalence of diabetes
was higher for the angiotensin receptor blocker and
lisinopril groups than for the cardiovascular compara-
tor (table 1), which is to be expected in routine care as
both angiotensin receptor blockers and lisinopril are
frequently prescribed for people with diabetes. Each
of the differences in comorbid illnesses was statistically
significant (P<0.001) because of the large number of
people in each group. Mean systolic and diastolic
blood pressures were similar between groups (table 1).
Incident Alzheimer’s disease and dementia
Figure 1 shows the survival curves for incident Alzhei-
mer’s disease and dementia among participants in the
three groups (see web extra table 1 for the unadjusted
incident rates). Angiotensin receptor blockers were
associated with significant reductions in incident Alz-
heimer’s disease compared with lisinopril (hazard rate
0.81, 95% confidence interval 0.68 to 0.96, P=0.016;
table 2) or the cardiovascular comparator (0.84, 0.71
to 1.00, P=0.045; table 2). More participants devel-
oped incident dementia than incident Alzheimer’s
disease, although the results were similar to those for
Alzheimer’s disease. Angiotensin receptor blockers
were also associated with significant reductions in inci-
dent dementia compared with lisinopril (0.81, 0.73 to
0.90, P<0.001) or the cardiovascular comparator (0.76,
0.69 to 0.84, P<0.001; table 2). Adding hypertension
and renal insufficiency as covariates did not change the
outcomes (data not shown).
Admission to nursing homes and death
Web table 2 shows the unadjusted rates for admission
to nursing homes of people with Alzheimer’s disease
and death among patients with a diagnosis of Alzhei-
mer’s disease and dementia. From the Cox propor-
tional hazards models users of angiotensin receptor
blockers with Alzheimer’s disease showed signifi-
cantly lower rates of admissions to nursing homes
(0.51, 0.36 to 0.72, P=0.0001) and death (0.83, 0.71 to
0.97, P=0.022) compared with users of the cardio-
vascular comparator drugs (table 3). Similar results
were observed for patients with dementia (table 3).
Stroke was the strongest factor associated with dis-
ease incidence or admission to a nursing home but a
weaker factor in relation to death (tables 2 and 3).
Graded drug effects
Sufficient numbers of participants used candesartan,
irbesartan, losartan, or valsartan to study dose-
response effects (see web extra table 4). Each drug
showed a clear dose-response relation, with higher
doses associated with lower rates of incident dementia
(table 4). For example, among participants in the high
dose candesartan group the hazard rate for incident
dementia was 27% lower than that in the low dose
group.During the study the use of valsartan (and losar-
tan) increased (see web extra fig 1).
Table 3 | Cox proportional hazard model for association between angiotensin receptor blockers and disease progression (admission to nursing home or
death) among participants with Alzheimer’s disease or dementia
Comparison groups
Admission to nursing home Death
Estimate (SE) P value Hazard rate (95% CI) Estimate (SE) P value Hazard rate* (95% CI)
Alzheimer’s disease:
Angiotensin receptor blocker v lisinopril −0.458 (0.182) 0.0119 0.63 (0.44 to 0.90) −0.163 (0.084) 0.054 0.85 (0.72 to 1.00)
Angiotensin receptor blocker v cardiovascular comparator −0.671 (0.177) 0.0001 0.51 (0.36 to 0.72) −0.187 (0.081) 0.022 0.83 (0.71 to 0.97)
Lisinopril v cardiovascular comparator −0.213 (0.062) 0.0006 0.81 (0.72 to 0.91) −0.024 (0.033) 0.463 0.98 (0.92 to 1.04)
Age 0.025 (0.005) <0.001 1.03 (1.02 to 1.04) 0.053 (0.003) <0.001 1.05 (1.05 to 1.06)
Cardiovascular disease 0.235 (0.055) <0.001 1.27 (1.14 to 1.41) −0.019 (0.028) 0.493 0.98 (0.93 to 1.04)
Diabetes 0.347 (0.053) <0.001 1.41 (1.28 to 1.57) 0.096 (0.029) 0.001 1.10 (1.04 to 1.17)
Stroke 0.556 (0.052) <0.001 1.74 (1.57 to 1.93) 0.016 (0.029) 0.595 1.02 (0.96 to 1.08)
Dementia:
Angiotensin receptor blocker v lisinopril −0.308 (0.084) 0.0002 0.74 (0.62 to 0.87) −0.139 (0.044) 0.001 0.87 (0.80 to 0.95)
Angiotensin receptor blocker v cardiovascular comparator −0.491 (0.081) <0.001 0.61 (0.52 to 0.72) −0.120 (0.042) 0.004 0.89 (0.82 to 0.96)
Lisinopril v cardiovascular comparator −0.184 (0.032) <0.001 0.83 (0.78 to 0.89) 0.019 (0.018) 0.279 1.02 (0.99 to 1.06)
Age 0.027 (0.002) <0.001 1.03 (1.02 to 1.03) 0.056 (0.001) <0.001 1.06 (1.06 to 1.06)
Cardiovascular disease 0.326 (0.031) <0.001 1.39 (1.30 to 1.47) 0.026 (0.016) 0.112 1.03 (0.99 to 1.06)
Diabetes 0.282 (0.028) <0.001 1.33 (1.26 to 1.40) 0.078 (0.016) <0.001 1.08 (1.05 to 1.12)
Stroke 0.588 (0.028) <0.001 1.80 (1.71 to 1.90) 0.065 (0.015) <0.001 1.07 (1.04 to 1.10)
*Adjusted for age, stroke, cardiovascular disease, and diabetes.
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A multidrug use model was used to examine
whether participants who switched from angiotensin
converting enzyme inhibitors to angiotensin receptor
blockers, or the converse, adopted the dementia
hazard rate for the subsequent drug. Participants were
not excluded for usingmore than one drug type during
the study. Participants were those without a previous
diagnosis of dementia who were prescribed angioten-
sin receptor blockers or angiotensin converting
enzyme inhibitors (but not both) and showed stable
use of the drug over the first six months after entry
into the study on the basis of a drug possession ratio
of 80% or greater. All relevant drugs included in the
Veteran Affairs health system formulary were used
by the angiotensin converting enzyme inhibitors
group. Participants who used angiotensin receptor
blockers throughout the study or who started using
angiotensin converting enzyme inhibitors and
switched to angiotensin receptor blockers showed a
significantly lower odds of incident dementia than the
reference group that did not switch from angiotensin
converting enzyme inhibitors throughout the study
(0.28, 0.24 to 0.32, P<0.001; table 5). However, parti-
cipants who initially received angiotensin receptor
blockers but then switched to angiotensin converting
enzyme inhibitors showed a non-significantly different
risk of incident dementia than the reference group
(table 5).
Additive effects
As angiotensin receptor blockers and angiotensin con-
verting enzyme inhibitors both decrease signalling
through the AT1 receptor, we hypothesised that their
combined usemight result in added inhibition, leading
to enhanced clinical efficacy. We examined the effects
of combined use on incident Alzheimer’s disease or
dementia among participants without a previous diag-
nosis of dementia, and on nursing home admissions
among participants with pre-existing Alzheimer’s
disease or dementia. Combined use was generally
associated with lower outcome rates than use of angio-
tensin receptor blockers alone, angiotensin converting
enzyme inhibitor alone, or lisinopril alone (fig 2 and
web extra table 5). For example, the hazard rate for
the drug combination compared with angiotensin con-
verting enzyme inhibitors alone for incident Alzhei-
mer’s disease was 0.45 (0.41 to 0.50, P<0.001) and for
dementia was 0.54 (0.51 to 0.57, P<0.001, fig 2 and
web extra table 5). The hazard rate for admission to a
nursing home among patients with dementia was 0.33
(0.22 to 0.49, P<0.001) for combined use of
angiotensin receptor blockers and angiotensin con-
verting enzymes compared with lisinopril or any
angiotensin converting enzyme inhibitor alone (fig 2
and web extra table 5).
DISCUSSION
This study suggests that angiotensin receptor blockers
are associated with reduced incidence and progression
of Alzheimer’s disease and dementia compared with
other drugs for cardiovascular disease or hypertension.
One of the measures used for disease progression was
admission to a nursing home. The robust reduction in
such admissions associated with use of angiotensin
receptor blockers is a particularly important observa-
tion that could have a major impact on public health if
validated by future studies. The strength and consis-
tency of the effect over several different analyses sup-
ports the validity of this finding.
Use of angiotensin receptor blockers was associated
with a significant dose-response profile for incident
dementia, with the brain penetrant angiotensin recep-
tor blocker candesartan showing the strongest dose
dependent reduction in incident dementia. Lisinopril,
one of the main comparators, is not a brain penetrant,
although whether brain penetration increases with
dementia is unknown.41 However, when we compared
the effects of angiotensin receptor blockers with that of
the entire group of angiotensin converting enzyme
inhibitors (see table 4), switching from angiotensin
converting enzyme inhibitors to angiotensin receptor
blockers was also associatedwith reductions in demen-
tia. This suggests that selection bias linked to initial
assignment of treatment with either drug class does
not determine the outcome. Finally, both drug classes
showed additive benefits, which is consistent with their
mutual activity at the AT1 receptor. Additive effects
were observed for lisinopril alone and for angiotensin
converting enzyme inhibitors generally (fig 2 and web
extra table 5). The additive benefits of both drug
classes is consistent with recent prospective clinical
trials.24 Combination therapy therefore could be parti-
cularly beneficial for patients.
For the study of incident Alzheimer’s disease and
dementia, we examined drugs using a “single drug”
model that restricted drug classes to one particular
group on entry and for the duration of the study. The
other studies had fewer participants, which required
use of a polypharmacy model to obtain sufficient
power. In the polypharmacy model, use of lisinopril
or angiotensin converting enzyme inhibitors was disal-
lowed for participants in the angiotensin receptor
blocker cohort entering the study; however, addition
of either was allowed any time beyond sixmonths after
study entry. The rationale for the polypharmacy
approach is that angiotensin receptor blockers might
showa “gain of protection” comparedwith angiotensin
converting enzyme inhibitors. The effects associated
with additive drug use and with switching between
the two drug classes (see tables 4 and 5) indicate that
angiotensin receptor blockers are associated with bet-
ter outcomes than use of angiotensin converting
Table 4 | Effect of angiotensin receptor blocker dosage (high v low) on incidence of dementia
Angiotensin receptor blocker Estimate (SE) P value Hazard rate* (95% CI)
Candesartan −0.322 (0.076) <0.001 0.73 (0.62 to 0.84)
Irbesartan −0.174 (0.044) <0.001 0.84 (0.77 to 0.92)
Losartan −0.200 (0.066) 0.0025 0.82 (0.72 to 0.93)
Valsartan −0.103 (0.198) 0.602 0.91 (0.61 to 1.33)
*Cox proportional hazard model adjusted for age, cardiovascular disease, diabetes, and stroke.
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enzyme inhibitors, as shown by the greater effect
observed with a higher dose and with combined use
of angiotensin receptor blockers and angiotensin con-
verting enzyme inhibitors.
Strengths and limitations of the study
An important strength of our studywas the use of com-
parators from the same class of drugs, which allowed
cohorts that share similar demographic, health status,
and hospital utilisation profiles to be compared. Our
study covered a five year period. A longer time frame,
however, might be associated with a more robust
outcome because studies show that cardiovascular
risk factors exert their impact on dementia beginning
in mid-life.42-45
Misclassification, such as misdiagnosis or missing
information, is an important factor that could bias the
data. We compared rates of participants lost to follow-
up in each cohort but observed no significant differ-
ences. We also included Alzheimer’s disease and
dementia as independent outcomes to control for pro-
blems with diagnostic sensitivity or specificity asso-
ciated with population derived databases. In addition,
misclassification would seem to bias towards the null
hypothesis. Studies of population databases are prone
to other unanticipated biases. Comorbiditiesmight dif-
fer among the cohorts. Indeed, diabetes and stroke
were significantly associated with some of the out-
comes. However, such conditions are associated with
higher rates of Alzheimer’s disease and dementia,
which would tend to decrease the size of any associa-
tion of angiotensin receptor blockers with reduced
rates of these diseases. Although we compared mean
blood pressure between the groups (no differences
were observed), we did not determine mean blood
pressure lowering for angiotensin receptor blockers
and angiotensin converting enzyme inhibitors. Studies
have suggested that these drug classes achieve similar
levels of blood pressure lowering, differences between
the groups could contribute to the putative benefit
towards dementia associatedwith angiotensin receptor
blocker use.13 Multiple indication bias could dilute the
effects of our findings but this would bias towards the
null hypothesis. Under-diagnosis exists in the decision
support system database, but our three cohorts had
similar rates of hospital utilisation.
The open nature of themedical system in theUnited
States also raises the possibility of a bias among parti-
cipants using the Veterans Affairs healthcare system.
One study showed high rates of use of the Veterans
Affairs healthcare system by patients for primary
health care and primary pharmacy sources.46 Our
study incorporated losses to follow-up as an exclusion
criterion, but omission of this from the model yielded
similar outcomes, suggesting that only minor differ-
ences existed for source of healthcare use among the
cohorts. Additional bias could come from several
sources. Admission to a nursing home depends on fac-
tors that are independent of dementia, such as the abil-
ity of care givers to care for patients. Bias can also come
from nursing home use, as participants can vary in
their choice of nursing homes affiliated with the Veter-
ans Affairs system or private systems. About half of the
participants in theVeteransAffairs system choose nur-
sing homes affiliated with the Veterans Affairs.47 Ana-
lysis of nursing home admissions on the basis of
nursing homes affiliated with the Veterans Affairs
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Fig 2 | Additive effects of angiotensin receptor blockers (ARB) and angiotensin converting
enzyme (ACE) inhibitors compared with single drug use. Hazard rates (95% confidence
intervals) are adjusted for age, stroke, diabetes, and cardiovascular disease
Table 5 | Effects of switching drug class on incidence of dementia
Variables Estimate (SE) P value Hazard rate* (95% CI)
Variables:
Angiotensin receptor blocker to angiotensin receptor blocker† −0.73 (0.018) <0.001 0.48 (0.47 to 0.50)
Angiotensin receptor blocker to angiotensin converting enzyme inhibitor‡ 0.16 (0.169) 0.3562 1.17 (0.84 to 1.63)
Angiotensin converting enzyme inhibitor to angiotensin receptor blocker§ −1.28 (0.073) <0.001 0.28 (0.24 to 0.32)
Covariables:
Age 0.09 (0.001) <0.001 1.10 (1.09 to 1.10)
Cardiovascular disease 0.12 (0.017) <0.001 1.13 (1.09 to 1.17)
Diabetes 0.28 (0.016) <0.001 1.33 (1.29 to 1.37)
Stroke 0.96 (0.016) <0.001 2.61 (2.53 to 2.69)
Reference group: angiotensin converting enzyme inhibitor to angiotensin converting enzyme inhibitor.
*Cox proportional hazard model adjusted for age, stroke, diabetes, and cardiovascular disease.
†Participants used angiotensin receptor blocker throughout study.
‡Participants switched from angiotensin receptor blocker to angiotensin converting enzyme inhibitor by end of study.
§Participants switched from angiotensin converting enzyme inhibitor to angiotensin receptor blocker by end of study.
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system might introduce a general selection bias in our
cohorts, but such bias needs to be assessed in the con-
text of similar rates of losses to follow-up and use of
cohorts based on similar drug classes that are also simi-
lar by other measures examined. Characterisation of
bias in choice of nursing homes requires harmonisa-
tion of the Veterans Affairs and Medicare databases,
which has not yet been achieved. Other unanticipated
biases might also exist due to unmeasured variables,
such as instrumental variables (for example, income,
exercise). None the less, pharmacoepidemiological
studies of drugs on risk of dementia need to be evalu-
ated in large populations that permit adequate statisti-
cal power to control for confounding by indication.
The present study is the first to compare both risk of
dementia and progression of dementia in users of
angiotensin receptor blockers compared with users of
a drug from the same class (lisinopril) or users of other
drugs prescribed for cardiovascular disease.
Biological mechanisms
Stroke was consistently ranked as the most important
covariate in our dataset. The strong association of stroke
with dementia and nursing home admission in our study
is consistentwith previous studies, suggesting the impor-
tance of vascular factors in progression of cognitive
loss.48-50 Decreased cerebral blood flow is a common
and early observation among people with Alzheimer’s
disease.49 Previous studies suggest that angiotensin
receptor blockers offer an important advantage over
angiotensin converting enzyme inhibitors and other
antihypertensive agents in improving outcomes from
stroke.751-53 Recent results from the Ongoing Telmisar-
tan Alone and in Combination with Ramipril Global
Endpoint Trial (ONTARGET), which examined the
effects of telmisartan plus ramipril, observed a decrease
in secondary stroke associated with use of telmisartan,
but the lowering of stroke rates did not reach
significance.54 Animal studies report that angiotensin
receptor blockers elicit neuroprotective responses that
are independent of decreases in blood pressure and are
apparent even in cell culture.1852 Vascular dysfunction
induced by amyloid β, the protein that accumulates in
Alzheimer’s disease, plays an important part in the dis-
ease. Loss of cerebral blood flow is a prominent and
early feature of the disease, perhaps as a result of the
accumulation of amyloid β.495556 Angiotensin receptor
blockers seem to be particularly effective at preventing
vascular damage inducedbyamyloid β.57-59 Because vas-
cular dysfunction and stroke are associated with cogni-
tive decline, our data raise the possibility that combined
use of angiotensin receptor blockers and angiotensin
converting enzyme inhibitorsmight confer superiorpro-
tection against cognitive decline (compared with other
cardiovascular drugs) by reducing neuronal damage
associated with stroke and vascular dysfunction.
Diabetes is a strong risk factor for Alzheimer’s dis-
ease and dementia, and diabetes was a significant cov-
ariate in our study.3 60 61 Clinical studies also indicate
that angiotensin receptor blockers offer superior pro-
tection against diabetes compared with other anti-
hypertensive drugs.13 23 Angiotensin receptor blocker
mediated protection against deleterious effects of dia-
betes might also contribute to the positive results
observed in this study. The biochemical mechanisms
contributing to the putative beneficial clinical out-
comes resulting from modulation of the renin-angio-
tensin system are difficult to identify and could be
pleiotropic. Potential mechanisms are reviewed
elsewhere.32 33 Regardless of the mechanism, our
study suggests that selective blockade of the angioten-
sin II receptor AT1 offers important health benefits to
those with cognitive decline, and combined use of
angiotensin receptor blockers and angiotensin con-
verting enzyme inhibitors is associated with even
greater benefits.
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